Reboxetine and citalopram in panic disorder: A single-blind, cross-over, flexible-dose pilot study

Simple item page
dc.contributor.authorSeedat S.
dc.contributor.authorVan Oudtshoorn E.V.R.
dc.contributor.authorMuller J.E.
dc.contributor.authorMohr N.
dc.contributor.authorStein D.J.
dc.date.accessioned2011-05-15T15:59:17Z
dc.date.available2011-05-15T15:59:17Z
dc.date.issued2003
dc.description.abstractBoth noradrenergic and serotonergic systems have been implicated in the pathophysiology of panic disorder. The advent of selective serotonin (5-HT) reuptake inhibitors (SSRIs) (e.g. citalopram) and, more recently, selective noradrenergic (NA) reuptake inhibitors (NRIs) (e.g. reboxetine) has provided potentially important avenues of treatment for the disorder. To date, the comparative efficacy of selective NA and 5-HT reuptake inhibitors for panic disorder remains unresolved. Nineteen patients with panic disorder were randomized in a single-blind, cross-over design to either citalopram or reboxetine for 8 weeks and after a 2-week washout were switched to the other study drug. At week 18, seven of 13 patients (54%) in the intent-to-treat sample responded to reboxetine and nine of 11 patients responded to citalopram (82%). Both citalopram and reboxetine led to significant improvements in panic attack severity with no apparent between-drug differences in efficacy. However, citalopram demonstrated superior efficacy in treating depressive symptoms. One non-responder to citalopram responded to reboxetine and three non-responders to reboxetine responded to citalopram. Although SSRIs are viewed as a first-line treatment for panic disorder, these results suggest that a NA agent such as reboxetine may also have a role. These data also suggest an advantage for citalopram in treating comorbid depressive symptoms, although some patients may respond preferentially to an SSRI and other patients to an NRI. © 2003 Lippincott Williams & Wilkins.
dc.description.versionArticle
dc.identifier.citationInternational Clinical Psychopharmacology
dc.identifier.citation18
dc.identifier.citation5
dc.identifier.issn2681315
dc.identifier.other10.1097/00004850-200309000-00004
dc.identifier.urihttp://hdl.handle.net/10019.1/11100
dc.subjectcitalopram
dc.subjectreboxetine
dc.subjectserotonin uptake inhibitor
dc.subjectadult
dc.subjectaged
dc.subjectanorexia
dc.subjectarticle
dc.subjectclinical article
dc.subjectclinical trial
dc.subjectcomorbidity
dc.subjectconstipation
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdisease severity
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjectdrug tolerability
dc.subjectdrug withdrawal
dc.subjectdysuria
dc.subjectfemale
dc.subjectfollow up
dc.subjectheadache
dc.subjecthot flush
dc.subjecthuman
dc.subjectinsomnia
dc.subjectloudness recruitment
dc.subjectmale
dc.subjectnausea
dc.subjectnoradrenergic system
dc.subjectpanic
dc.subjectparesthesia
dc.subjectpathophysiology
dc.subjectpriority journal
dc.subjectrandomized controlled trial
dc.subjectserotoninergic system
dc.subjectsexual dysfunction
dc.subjectside effect
dc.subjectsingle blind procedure
dc.subjectsweating
dc.subjectsyncope
dc.subjecttachycardia
dc.subjecttreatment outcome
dc.subjectvertigo
dc.subjectvisual impairment
dc.subjectxerostomia
dc.subjectyawning
dc.subjectAdministration, Oral
dc.subjectAdrenergic Uptake Inhibitors
dc.subjectAdult
dc.subjectCitalopram
dc.subjectComorbidity
dc.subjectCross-Over Studies
dc.subjectDepression
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMorpholines
dc.subjectPanic Disorder
dc.subjectPilot Projects
dc.subjectSerotonin Uptake Inhibitors
dc.subjectSingle-Blind Method
dc.subjectTreatment Outcome
dc.titleReboxetine and citalopram in panic disorder: A single-blind, cross-over, flexible-dose pilot study
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Publications